CA2293706C - Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase - Google Patents
Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase Download PDFInfo
- Publication number
- CA2293706C CA2293706C CA002293706A CA2293706A CA2293706C CA 2293706 C CA2293706 C CA 2293706C CA 002293706 A CA002293706 A CA 002293706A CA 2293706 A CA2293706 A CA 2293706A CA 2293706 C CA2293706 C CA 2293706C
- Authority
- CA
- Canada
- Prior art keywords
- aryl
- compound
- alkyl
- heterocycloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La présente invention concerne de nouveaux composés d'urée halogéno N-substitués et des compositions pharmaceutiquement acceptables de formules (1.0) ainsi que leurs sels ou solvates pharmaceutiquement acceptables, qui sont des inhibiteurs de l'enzyme farnésyl transférase. La présente invention concerne également une méthode d'inhibition de la fonction Ras et donc de la croissance anormale des cellules. Cete méthode, qui consiste à administrer le nouveau composé d'urée halogéno N-substitué à un système biologique permet notamment d'inhiber la croissance anormale des cellules chez des mammifères tel que l'homme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87704997A | 1997-06-17 | 1997-06-17 | |
US08/877,049 | 1997-06-17 | ||
PCT/US1998/011507 WO1998057948A1 (fr) | 1997-06-17 | 1998-06-15 | Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2293706A1 CA2293706A1 (fr) | 1998-12-23 |
CA2293706C true CA2293706C (fr) | 2008-11-18 |
Family
ID=25369144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002293706A Expired - Fee Related CA2293706C (fr) | 1997-06-17 | 1998-06-15 | Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0989979A1 (fr) |
JP (1) | JP2002506444A (fr) |
KR (1) | KR20010013881A (fr) |
CN (1) | CN1267291A (fr) |
AR (1) | AR013094A1 (fr) |
AU (1) | AU8253598A (fr) |
CA (1) | CA2293706C (fr) |
CO (1) | CO4940458A1 (fr) |
HU (1) | HUP0002954A3 (fr) |
IL (1) | IL133389A0 (fr) |
NZ (1) | NZ501571A (fr) |
PE (1) | PE82799A1 (fr) |
WO (1) | WO1998057948A1 (fr) |
ZA (1) | ZA985205B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
HUP0302913A3 (en) * | 2000-10-05 | 2005-05-30 | Daley George Q Weston | Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same |
AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
EP1695961A4 (fr) * | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | Derives d'uree, processus de production correspondant et utilisation |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Kras g12c之共價抑制劑 |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質のインヒビター |
WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356349A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (fr) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3364977A4 (fr) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | Méthode de criblage d'inhibiteurs de ras |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3519402A1 (fr) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
EP3573964A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
WO2018140512A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation |
EP3573970A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
EP3573971A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
EP3573967A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
WO2018218069A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
CA3063440A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Inhibiteurs covalents de kras |
CN111960990A (zh) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | 一种助剂及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
IL125062A (en) * | 1995-12-22 | 2003-11-23 | Schering Corp | Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases |
ES2234036T3 (es) * | 1996-09-13 | 2005-06-16 | Schering Corporation | Compuestos utiles para inhibir la farnesil-protein-transferasa. |
CZ87499A3 (cs) * | 1996-09-13 | 1999-08-11 | Schering Corporation | Substituované deriváty benzocykloheptapyridinu použitelné při léčbě nádorových onemocnění tím, že inhibují farnesylprotein transferázu |
-
1998
- 1998-06-15 EP EP98932717A patent/EP0989979A1/fr not_active Withdrawn
- 1998-06-15 PE PE1998000506A patent/PE82799A1/es not_active Application Discontinuation
- 1998-06-15 KR KR1019997011903A patent/KR20010013881A/ko not_active Application Discontinuation
- 1998-06-15 HU HU0002954A patent/HUP0002954A3/hu unknown
- 1998-06-15 CA CA002293706A patent/CA2293706C/fr not_active Expired - Fee Related
- 1998-06-15 WO PCT/US1998/011507 patent/WO1998057948A1/fr not_active Application Discontinuation
- 1998-06-15 CN CN98808189A patent/CN1267291A/zh active Pending
- 1998-06-15 JP JP50450299A patent/JP2002506444A/ja not_active Ceased
- 1998-06-15 AU AU82535/98A patent/AU8253598A/en not_active Abandoned
- 1998-06-15 IL IL13338998A patent/IL133389A0/xx unknown
- 1998-06-15 ZA ZA985205A patent/ZA985205B/xx unknown
- 1998-06-15 NZ NZ501571A patent/NZ501571A/en unknown
- 1998-06-16 AR ARP980102858A patent/AR013094A1/es unknown
- 1998-06-16 CO CO98034144A patent/CO4940458A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU8253598A (en) | 1999-01-04 |
IL133389A0 (en) | 2001-04-30 |
JP2002506444A (ja) | 2002-02-26 |
WO1998057948A1 (fr) | 1998-12-23 |
CO4940458A1 (es) | 2000-07-24 |
CA2293706A1 (fr) | 1998-12-23 |
PE82799A1 (es) | 1999-08-26 |
HUP0002954A2 (hu) | 2001-06-28 |
CN1267291A (zh) | 2000-09-20 |
NZ501571A (en) | 2002-02-01 |
ZA985205B (en) | 1998-12-15 |
KR20010013881A (ko) | 2001-02-26 |
EP0989979A1 (fr) | 2000-04-05 |
AR013094A1 (es) | 2000-12-13 |
HUP0002954A3 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2293706C (fr) | Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase | |
US6358968B1 (en) | N-substituted urea inhibitors of farnesyl-protein transferase | |
WO1998057946A1 (fr) | Composes tricycliques de carboxy piperidylacetamide utilises pour inhiber une fonction g-proteine et traiter des maladies proliferatives (inhibiteurs de farnesyl proteine transferase) | |
EP0927178B1 (fr) | Composes tricycliques inhibant la fonction de la proteine g et traitant les maladies proliferantes | |
CA2293672C (fr) | Derives tricycliques de ceto-amides s'utilisant comme inhibiteurs de la transferase de proteine de farnesyl | |
EP0927181A1 (fr) | Composes tricycliques servant a inhiber la farnesyl-proteine transferase | |
CA2293358C (fr) | Sulfonamides tricycliques servant a inhiber la farnesyl-proteine transferase | |
AU5196698A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
US6218401B1 (en) | Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase | |
US6426352B1 (en) | Sulfonamide inhibitors of farnesyl-protein transferase | |
CA2261724C (fr) | Nouvelles n-cyano-imines tricycliques utiles en tant qu'inhibiteurs de la farnesyle transferase | |
CA2293553C (fr) | Composes tricycliques aminooxyamide inhibiteurs de farnesyl-proteine transferase | |
MXPA99012069A (en) | Novel n-substituted urea inhibitors of farnesyl-protein transferase | |
EP0927179B1 (fr) | Derives substitues de la benzocycloheptapyridine utiles pour l'inhibition de la farnesyl transferase | |
CA2293373C (fr) | Derives de benzo(5,6)cyclohepta(1,2b)pyridine s'utilisant comme inhibiteurs de transferase de proteine de farnesyl | |
EP0993460A1 (fr) | Derives de benzo(5,6)cyclohepta(1,2-b)pyridine inhibiteurs de la farnesyl proteine transferase | |
CA2293549C (fr) | Composes tricycliques substitues de phenyle servant a inhiber la farnesyl-proteine transferase | |
MXPA99012080A (en) | Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase | |
MXPA99012084A (en) | Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase | |
MXPA99012087A (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |